ABSTRACT
Ameloblastoma (AM) is considered one of the most common lesions of odontogenic origin. Although it is always considered as benign neoplasm, ameloblastic carcinoma (AC) represents its malignant counterpart. It is characterized by the expansion of jaws, rapid growth, and a perforated cortex with well-defined unilocular/multilocular radiolucent lesions. To confirm the diagnosis of AM and AC is extremely crucial. Immunohistochemistry such as SOX2 and Ki67 plays a significant role in the confirmation of diagnosis. Management of these cases is from surgical excision with radical neck dissection. The prognosis is poor with only 5 years of survival. This review presents an interesting case of ex-AC, in which the patient was diagnosed at the same site with peripheral AM 1 year ago.
ABSTRACT
The treatment of cancer has remarkably improved because of increased knowledge of the abnormalities at the molecular level, which results in human cancer growth. This has initiated the development of ever more successful as well as effective targeted cancer therapies. Detection of cancer is diagnosed basically by performing routine biopsy/cytology, which has many drawbacks. Therefore, the concept of liquid biopsy has been introduced to oncology, which has the potential to revolutionise the management of cancer patients, eliminating the invasive procedures needed to obtain tissue samples and provide information. Liquid biopsy is the analysis of tumour cells or tumour cell products obtained from blood or other body fluids, providing a broad range of opportunities in the field of pathology. Here, we focus on the most prominent liquid biopsy markers, circulating tumour cells and circulating tumour-derived deoxyribonucleic acid (DNA), in the blood of patients. In this review, we discuss recent clinical studies on these biomarkers for early detection and prognostication of cancer, which helps in successful management. Hence, liquid biopsy is introduced with great promise for personalised medicine because of its ability to provide multiple non-invasive snapshots of the primary and metastatic tumours.
ABSTRACT
With this article we present our initial experience with interventional sialendoscopy of the parotid duct for the parotid calculi. We carried out a prospective study of patients of parotid calculi in a tertiary referral centre. Diagnostic and interventional sialendoscopy was performed in five cases of parotid calculi. The outcome was classified on the basis of clearance of the lumen of the duct and resolution of symptoms. Diagnostic sialendoscopy was able to diagnose the calculus in all cases. Interventional sialendoscopy was done under general anesthesia in all cases and calculus was successfully removed. The average size of sialolith was 8.2 mm. No complications occurred in any of the cases. Check sialendoscopy was done in all cases after a minimum follow up of 6 months, which showed the duct lumen to be free of stone with no stricture of the duct. Sialendoscopy is an optimal technique for removal of intraductal parotid calculi and avoids removal of the gland. In our series there was no associated morbidity and complication.
